JP2021502102A - 細胞 - Google Patents

細胞 Download PDF

Info

Publication number
JP2021502102A
JP2021502102A JP2020526075A JP2020526075A JP2021502102A JP 2021502102 A JP2021502102 A JP 2021502102A JP 2020526075 A JP2020526075 A JP 2020526075A JP 2020526075 A JP2020526075 A JP 2020526075A JP 2021502102 A JP2021502102 A JP 2021502102A
Authority
JP
Japan
Prior art keywords
cell
cells
nucleic acid
enzymes
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020526075A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502102A5 (cg-RX-API-DMAC7.html
Inventor
サイモン トーマス,
サイモン トーマス,
マーティン プーレ,
マーティン プーレ,
ポール スミス,
ポール スミス,
アイザック ギャノン,
アイザック ギャノン,
ウィリアム バランド,
ウィリアム バランド,
Original Assignee
オートラス リミテッド
オートラス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オートラス リミテッド, オートラス リミテッド filed Critical オートラス リミテッド
Publication of JP2021502102A publication Critical patent/JP2021502102A/ja
Publication of JP2021502102A5 publication Critical patent/JP2021502102A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
JP2020526075A 2017-11-13 2018-11-12 細胞 Withdrawn JP2021502102A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1718697.4A GB201718697D0 (en) 2017-11-13 2017-11-13 Cell
GB1718697.4 2017-11-13
PCT/GB2018/053262 WO2019092442A1 (en) 2017-11-13 2018-11-12 Cell

Publications (2)

Publication Number Publication Date
JP2021502102A true JP2021502102A (ja) 2021-01-28
JP2021502102A5 JP2021502102A5 (cg-RX-API-DMAC7.html) 2021-10-28

Family

ID=60788303

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020526075A Withdrawn JP2021502102A (ja) 2017-11-13 2018-11-12 細胞

Country Status (8)

Country Link
US (1) US20200345776A1 (cg-RX-API-DMAC7.html)
EP (1) EP3710045A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021502102A (cg-RX-API-DMAC7.html)
CN (1) CN111344006A (cg-RX-API-DMAC7.html)
AU (1) AU2018364490A1 (cg-RX-API-DMAC7.html)
CA (1) CA3082265A1 (cg-RX-API-DMAC7.html)
GB (1) GB201718697D0 (cg-RX-API-DMAC7.html)
WO (1) WO2019092442A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
EP3934666A1 (en) 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
CN117043180A (zh) * 2020-09-11 2023-11-10 新加坡国立大学 用于器官移植患者的免疫疗法的免疫抑制剂药物抗性装甲tcr t细胞
CN116463362B (zh) * 2023-06-15 2023-09-19 中国中医科学院中药研究所 一种细胞分裂抑制剂的制备方法
CN117384931B (zh) * 2023-12-06 2024-03-08 中国中医科学院中药研究所 一种GSK-3β抑制剂的制备方法

Also Published As

Publication number Publication date
CN111344006A (zh) 2020-06-26
US20200345776A1 (en) 2020-11-05
GB201718697D0 (en) 2017-12-27
CA3082265A1 (en) 2019-05-16
EP3710045A1 (en) 2020-09-23
WO2019092442A1 (en) 2019-05-16
AU2018364490A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
AU2017371517B2 (en) Engineered natural killer cells and uses thereof
KR102601849B1 (ko) 키메라 단백질
CN107206024B (zh) 改变cart细胞中的基因表达及其用途
EP3681995B1 (en) Cell
US20200345776A1 (en) Cell
JP2017533706A (ja) 改変t細胞に関する方法および組成物
CN110461881A (zh) 嵌合抗原受体
US12552852B2 (en) Chimeric antigen receptor t lymphocyte for treating tumors, preparation method therefor, and use thereof
CN114555789A (zh) 工程化免疫细胞
JP6842688B2 (ja) キメラ抗原受容体
JP2021520792A (ja) 操作された細胞溶解性免疫細胞
CA3215822A1 (en) Chimeric antigen receptor (car)-t cells
JP7054181B2 (ja) キメラ抗原受容体
HK40061900A (en) Engineered natural killer cells and uses thereof
HK40061900B (en) Engineered natural killer cells and uses thereof
WO2021123802A1 (en) Cell
HK40018917B (en) Engineered natural killer cells and uses thereof
HK40018917A (en) Engineered natural killer cells and uses thereof
KR20210142665A (ko) 세포 사멸에 대한 증가된 내성을 갖는 변형된 면역 효과기 세포
NZ757552B2 (en) Chimeric antigen receptor
HK1262291A1 (en) Engineered natural killer cells and uses thereof
HK1262291B (en) Engineered natural killer cells and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210914

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220316